Shares of Cardiovascular Systems Inc. (NASDAQ:CSII) have earned an average recommendation of “Buy” from the nine research firms that are covering the firm. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $25.40.

A number of analysts have recently weighed in on the stock. Leerink Swann raised shares of Cardiovascular Systems from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a research note on Monday, August 22nd. Zacks Investment Research lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th. Needham & Company LLC upped their price target on shares of Cardiovascular Systems from $23.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, August 4th. Finally, Bank of America Corp. raised shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th.

In other news, SVP Paul A. Koehn sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $22.17, for a total transaction of $88,680.00. Following the sale, the senior vice president now owns 102,652 shares in the company, valued at $2,275,794.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Paul A. Koehn sold 5,969 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $25.02, for a total transaction of $149,344.38. Following the sale, the senior vice president now owns 73,321 shares in the company, valued at approximately $1,834,491.42. The disclosure for this sale can be found here. Corporate insiders own 5.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. raised its stake in Cardiovascular Systems by 20.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 112,589 shares of the medical device company’s stock worth $2,069,000 after buying an additional 18,774 shares in the last quarter. Numeric Investors LLC purchased a new stake in Cardiovascular Systems during the second quarter worth about $373,000. Point72 Asset Management L.P. raised its stake in Cardiovascular Systems by 295.1% in the second quarter. Point72 Asset Management L.P. now owns 403,824 shares of the medical device company’s stock worth $7,420,000 after buying an additional 301,624 shares in the last quarter. Weiss Multi Strategy Advisers LLC raised its stake in Cardiovascular Systems by 45.8% in the second quarter. Weiss Multi Strategy Advisers LLC now owns 14,580 shares of the medical device company’s stock worth $268,000 after buying an additional 4,580 shares in the last quarter. Finally, Barclays PLC raised its stake in Cardiovascular Systems by 246.5% in the second quarter. Barclays PLC now owns 15,376 shares of the medical device company’s stock worth $283,000 after buying an additional 10,939 shares in the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

Shares of Cardiovascular Systems (NASDAQ:CSII) opened at 23.39 on Thursday. The stock’s market capitalization is $779.94 million. Cardiovascular Systems has a 1-year low of $7.50 and a 1-year high of $25.22. The firm has a 50-day moving average of $23.08 and a 200 day moving average of $17.24.

Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, August 3rd. The medical device company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.05. Cardiovascular Systems had a negative net margin of 31.44% and a negative return on equity of 38.39%. The firm earned $48.50 million during the quarter, compared to analysts’ expectations of $46.01 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. Cardiovascular Systems’s quarterly revenue was up .0% on a year-over-year basis. On average, equities analysts anticipate that Cardiovascular Systems will post ($0.62) earnings per share for the current fiscal year.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.

5 Day Chart for NASDAQ:CSII

Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.